Researchers reported last Wednesday (Oct 12, 2025) two promising new approaches to counteract malaria’s growing resistance to medication, one of which involves a new class of drugs.
Swiss multinational pharmaceutical company Novartis released results of what it called a next-generation treatment.
In a study involving about 1,700 adults and children in 12 African countries, the experimental drug was found to have a cure rate of better than 97%, which was a little higher than a common artemisinin-based treatment.
It was also highly effective against mutant
Continue Reading on The Star Malaysia
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.